Decreased Muscle Mass and Bone Minerals and Increased Abdominal “Inflammation” Were Revealed in Body Composition and Spectroscopy Analysis of Lean PCOS Patients – a Case-Control Study

Program: Abstracts - Orals, Poster Preview Presentations, and Posters
Session: MON 0057-0090-Hyperandrogenic Disorders
Translational
Monday, June 23, 2014: 1:00 PM-3:00 PM
Hall F (McCormick Place West Building)

Poster Board MON-0079
Charikleia Stefanaki1, Dario Boschiero2, Flora Bacopoulou, M.D., Ph.D.3, Evanthia Diamanti-Kandarakis, M.D., Ph.D.4 and George P. Chrousos, MD, PhD5
1Athens University Medical School, Athens, Greece, 2BIOTEKNA, 3University of Athens, Children's Hospital 'Aghia Sophia', Athens, Greece, 4Athens University Medical School, Athens, Greece, Athens, Greece, 5University of Athens School of Medicine, Athens, Greece
Limited data are available on the body composition of Polycystic Ovary Syndrome (PCOS) patients. In this case-control study, we aimed to elucidate the body composition differences between PCOS patients and their age- and weight- matched controls using Bio-Impedance (BIA) and BIA spectroscopy measures. Seventeen (17), lean PCOS patients and seventeen (17) healthy age- and weight- matched controls were studied. All underwent BIA and BIA spectroscopy analysis, using two advanced medical devices (BIA-ACC & TomEEx, Biotekna Co, Venice, Italy). The PCOS group demonstrated class I sarcopenia (x2 = 3414.167; df = 33; p=0.001), and low muscle mass, expressed as percentage of fat-free mass (Median = 31.1; U test = 28; p=0.001;, r = 0.7). Glycogen mass was also decreased in the PCOS group (PCOS: Median = 0.331, Control group: Mdn = 0.4, U test = 60; p=0.004;,r = 0.5). Fat mass did not differ statistically between the two groups (PCOS: Median = 13, Control: Mdn = 17.9; ns; U test = 133; r = 0.063) nor did the abdominal fat mass (PCOS: Mdn = 191.2, Control: Mdn = 273.88; ns; U test = 134; r = 0.06). Bone minerals and bone mass were decreased when compared to the control group results (PCOS: Mdn = 1.64, Control: Mdn =1.91; U test = 78; p = 0.02; r = 0.4/ PCOS: Mdn = 3, Control: Mdn = 3.53; U test = 74; p = 0.02;, r = 0.41). PCOS patients were dehydrated in terms of total body water volume and intracellular body water (PCOS: Median=53, Control: Mdn =57.487; U test = 10, p = 0.001, r = 0.799/ PCOS: Mdn = 14.9, Control:Median = 18; U test = 57; p = 0.002;, r = 0.52, respectively). Extracellular body water measured as percentage of total body water was increased in the PCOS group (PCOS: Median = 47, Control: Median = 42.51, U test = 10; p = 0.001; r = -0.8). Potassium was also decreased (PCOS: Median = 90, Control: Median = 108.841; U test = 59; p = 0.003; r = 0.507). TomEEx (BIA spectroscopy device) detected increased conductance in the anatomical areas of inferior abdomen (PCOS:Median = 27.60, Control: Median =0; U test =0; p =0.001; r =-0.91), superior abdomen (PCOS:Median = 6.7, Control: Median = 0; U test = 42.5; p = 0.000; r =-0.7) and lumbar area (PCOS:Median = 6.4, Control: Median = 0; U test=51; p = 0.000; r =-0.7). Our results demonstrate major differences in body composition between PCOS patients and healthy controls with decreased lean body mass in the former. They also imply that chronic low-grade inflammation is present in PCOS patients, which is consistent with the decreased muscle, glycogen and bone mass despite hyperandrogenemia. Skeletal muscle mitochondrial respiration is not impaired in PCOS; thus, their insulin resistance might be attributed to their decreased lean body mass. Lastly, bio-impedance spectroscopy revealed increased electrical conductance in the abdomen and lumbar area of PCOS patients. The significance of these findings and the utility of BIA spectroscopy as a potential screening tool for PCOS remain to be proved with further studies.

Disclosure: DB: Chief Scientific Officer, BIOTEKNA. Nothing to Disclose: CS, FB, ED, GPC

*Please take note of The Endocrine Society's News Embargo Policy at https://www.endocrine.org/news-room/endo-annual-meeting